Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

This study has been completed.
Information provided by (Responsible Party):
Dr. Chadi Nabhan, Oncology Specialists, S.C. Identifier:
First received: January 17, 2007
Last updated: January 29, 2013
Last verified: January 2013

Eligible patients will be enrolled in one of 4 cohorts where each cohort will allow 3 patients to be on study. Patients will receive both study drugs on escalated dosing schedule until the maximum of 400 mg PO BID is reached for both drugs or toxicity is established. Once the pre-specified 400 mg by mouth two times a day (PO BID) dosing for both drugs is reached without toxicity, the study will close for accrual. If toxicity is noted prior to reaching the 400 mg PO BID dosing, then the dosing schedule that is deemed safest as per study design will be the one used for any future phase II study.

Condition Intervention Phase
Prostate Cancer
Drug: Gleevec + Sorafenib
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study Investigating the Safety and Feasibility of Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-Independent Chemotherapy-Failure Prostate Cancer.

Resource links provided by NLM:

Further study details as provided by Oncology Specialists, S.C.:

Primary Outcome Measures:
  • Evaluate the safety and feasibility of combining Gleevec and Sorafenib [ Time Frame: During study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Overall Clinical Benefit measured as the sum of complete response (CR), partial response (PR), and stable disease (SD). [ Time Frame: During study ] [ Designated as safety issue: No ]
  • time to disease progression [ Time Frame: during study ] [ Designated as safety issue: No ]

Enrollment: 17
Study Start Date: January 2007
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib
Drug: Gleevec + Sorafenib
400 mg Sorafenib QD 300mg Gleevec QD
Other Name: Imatinib mesylate; Nexavar

Detailed Description:

Gleevec and Sorafenib have modest efficacy in androgen-independent prostate cancer (AIPC) and the fact that both agents can be given orally with what appears to be tolerable side effects, we hypothesize that combining both agents may provide patients with another effective regimen in a disease where therapeutic options are limited. This study is designed to investigate the safety of combining Gleevec and Sorafenib as well as feasibility in AIPC patients who have failed one or more lines of systemic chemotherapy. Once safety is established, a follow-up phase II study will commence to investigate efficacy.


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients 18 years of age or older.
  2. Histologically documented diagnosis of Prostate Cancer regardless of Gleason score.
  3. Androgen-Independent Prostate Cancer
  4. At least one measurable site of disease
  5. Patients must have failed one or more lines of systemic chemotherapy, regardless of the chemotherapeutic agent used. There is NO limit to how many lines of chemotherapy a patient can receive
  6. Patients receiving anti-coagulation treatment with an agent such as heparin may be allowed to participate. Patients on Warfarin are NOT allowed to participate.
  7. Last chemotherapy exposure 4 weeks prior to study entry
  8. Prior exposure to Sorafenib is allowed as long as last Sorafenib dose was 3 weeks or more from study entry
  9. Prior exposure to Gleevec is an EXCLUSION
  10. Progression after chemotherapy can be demonstrated radiographically (as per RECIST criteria) or biochemically with PSA being elevated more than 25% than previous value as long as a repeat PSA confirms progression. (repeat PSA should be done within 3 weeks from the last one). Patients with bone-only disease are considered progressing if there are two more lesions on a new bone scan.
  11. Performance status 0,1, 2 (ECOG)
  12. Adequate end organ function, defined as the following:

    • total bilirubin < 1.5 x ULN, SGOT and SGPT < 2.5 x UNL, creatinine < 1.5 x ULN, ANC > 1.0 x 109/L, platelets > 75 x 109/L.
  13. Men of childbearing potential must agree to employ an effective barrier method of birth control prior to the study entry, throughout the duration of the study and for up to 3 months following discontinuation of study drug.
  14. Written, voluntary informed consent.
  15. Patients are allowed the following concurrent therapies:

    • Intravenous bisphosphonates if administered for bone metastases
    • LHRH analogues
    • Narcotic-type medical interventions to control malignancy-related pain

Exclusion Criteria:

  1. Patient has received any other investigational agents within 21 days of first day of study drug dosing, unless the disease is rapidly progressing.
  2. Patient is < 3 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal or squamous cell skin cancer. Existence of any other malignant disease is not allowed.
  3. Patient with Grade III/IV cardiac problems
  4. Patient has a severe and/or uncontrolled medical disease
  5. Patient has a known brain metastasis.
  6. Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.
  7. Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
  8. Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug.
  9. Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.
  10. Serious non-healing wound, ulcer, or bone fracture.
  11. Use of St. John's Wort or rifampin (rifampicin).
  12. Any condition that impairs patient's ability to swallow whole pills.
  13. Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
  14. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
  15. Patient previously received radiotherapy to ³ 25 % of the bone marrow
  16. Patient had a major surgery within 2 weeks prior to study entry.
  17. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
  Contacts and Locations
Please refer to this study by its identifier: NCT00424385

United States, Illinois
Oncology Specialists, S.C
Niles, Illinois, United States, 60714
Oncology Specialists, S.C
Park Ridge, Illinois, United States, 60068
Sponsors and Collaborators
Oncology Specialists, S.C.
Principal Investigator: Chadi Nabhan, MD Oncology Specialists, SC
  More Information

No publications provided

Responsible Party: Dr. Chadi Nabhan, Principal Investigator, Oncology Specialists, S.C. Identifier: NCT00424385     History of Changes
Other Study ID Numbers: CST1571BUS260 (0617)
Study First Received: January 17, 2007
Last Updated: January 29, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Oncology Specialists, S.C.:
AIPC, Prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 23, 2014